Trial Profile
A phase II trial of CD24Fc in Graft versus host disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2016
Price :
$35
*
At a glance
- Drugs Efprezimod alfa (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 29 Mar 2016 New trial record